CombiGene is ending its epilepsy program to focus entirely on the COZY pain project for chronic pain treatment. Meanwhile, a cost reduction program is being implemented that is expected to result in net savings of approximately SEK 57 million up to and including Q2 2026.
- We want to use our existing cash to increase the company's value as effectively as possible. We believe we can do this by focusing on what we consider to be CombiGene's absolute core competence, says CEO Peter Ekolind.